Keros Therapeutics

Keros Therapeutics

Biotechnology
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

$217.4M

Market Cap • 11/20/2026

2015

(11 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,8

P/S

5,3

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

14,2

EPS

—

Market Cap

Market Cap

217,4M

EV

-26,9M

EV/Revenue

-0,7

EV/EBITDA

0,4

EV/EBIT

0,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

173,1%

Total Yield

173,1%

Payout

0%

Retained Earnings

-520M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

188,5%

Capex/Revenue

1%

Capex/D&A

26,5%

Capex/OCF

-0,9%

SBC/OCF

—

% PPE

5,9%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

2,5%

CAGR Net Income 5Y

-0,2%

CAGR EPS 5Y

0,8%

CAGR OCF 5Y

-1,1%

Leverage

N.D./EBITDA

3,4

Debt/Equity

0%

Current Ratio

18,1

Quick Ratio

17,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium